Dual Effects of Cellular Immunotherapy in Inhibition of Virus Replication and Prolongation of Survival in HCV-Positive Hepatocellular Carcinoma Patients
Immune cells play an important role in the development and progression of hepatitis C virus (HCV) and hepatocellular carcinoma (HCC). We conducted a retrospective study to evaluate the influence of adoptive cellular immunotherapy (CIT) on viral load and progression-free survival (PFS) for HCC patien...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2016-01-01
|
| Series: | Journal of Immunology Research |
| Online Access: | http://dx.doi.org/10.1155/2016/6837241 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849434714673250304 |
|---|---|
| author | Lei Qian Nanya Wang Huimin Tian Haofan Jin Hengjun Zhao Chao Niu Hua He Tingwen Ge Wei Han Jifan Hu Dan Li Fujun Han Jianting Xu Xiao Ding Jingtao Chen Wei Li Jiuwei Cui |
| author_facet | Lei Qian Nanya Wang Huimin Tian Haofan Jin Hengjun Zhao Chao Niu Hua He Tingwen Ge Wei Han Jifan Hu Dan Li Fujun Han Jianting Xu Xiao Ding Jingtao Chen Wei Li Jiuwei Cui |
| author_sort | Lei Qian |
| collection | DOAJ |
| description | Immune cells play an important role in the development and progression of hepatitis C virus (HCV) and hepatocellular carcinoma (HCC). We conducted a retrospective study to evaluate the influence of adoptive cellular immunotherapy (CIT) on viral load and progression-free survival (PFS) for HCC patients infected with HCV. Patients (n=104) were divided into a control group (conventional therapy, n=73) and study group (combination of CIT and conventional therapy, n=31). Autologous mononuclear cells were induced into natural killer, γδT, and cytokine-induced killer cells and infused intravenously to study group patients. More patients had shown viral load decrease or were stable in study group (100% versus 75%) (p=0.014). The median PFS of the study group and control group was 16 and 10 months, respectively (p=0.0041), and only CIT was an independent prognostic factor for PFS (hazard ratio, 0.422; p=0.005). Three patients developed transient moderate fever after infusion, and there were no significant differences in alanine aminotransferase and aspartate aminotransferase levels before and after treatment in both groups. Our results show that CIT contributes to improvement of prognosis and inhibition of viral replication in HCV-related HCC patients, without impairment of liver function. |
| format | Article |
| id | doaj-art-e378516b6982425a855d2726b1eec897 |
| institution | Kabale University |
| issn | 2314-8861 2314-7156 |
| language | English |
| publishDate | 2016-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Immunology Research |
| spelling | doaj-art-e378516b6982425a855d2726b1eec8972025-08-20T03:26:34ZengWileyJournal of Immunology Research2314-88612314-71562016-01-01201610.1155/2016/68372416837241Dual Effects of Cellular Immunotherapy in Inhibition of Virus Replication and Prolongation of Survival in HCV-Positive Hepatocellular Carcinoma PatientsLei Qian0Nanya Wang1Huimin Tian2Haofan Jin3Hengjun Zhao4Chao Niu5Hua He6Tingwen Ge7Wei Han8Jifan Hu9Dan Li10Fujun Han11Jianting Xu12Xiao Ding13Jingtao Chen14Wei Li15Jiuwei Cui16Department of Cancer Center, The First Hospital of Jilin University, Changchun 130021, ChinaDepartment of Cancer Center, The First Hospital of Jilin University, Changchun 130021, ChinaDepartment of Cancer Center, The First Hospital of Jilin University, Changchun 130021, ChinaDepartment of Cancer Center, The First Hospital of Jilin University, Changchun 130021, ChinaDepartment of Cancer Center, The First Hospital of Jilin University, Changchun 130021, ChinaDepartment of Cancer Center, The First Hospital of Jilin University, Changchun 130021, ChinaDepartment of Cancer Center, The First Hospital of Jilin University, Changchun 130021, ChinaDepartment of Cancer Center, The First Hospital of Jilin University, Changchun 130021, ChinaDepartment of Cancer Center, The First Hospital of Jilin University, Changchun 130021, ChinaDepartment of Cancer Center, The First Hospital of Jilin University, Changchun 130021, ChinaDepartment of Cancer Center, The First Hospital of Jilin University, Changchun 130021, ChinaDepartment of Cancer Center, The First Hospital of Jilin University, Changchun 130021, ChinaDepartment of Cancer Center, The First Hospital of Jilin University, Changchun 130021, ChinaDepartment of Cancer Center, The First Hospital of Jilin University, Changchun 130021, ChinaInstitute of Translational Medicine, The First Hospital of Jilin University, Changchun 130021, ChinaDepartment of Cancer Center, The First Hospital of Jilin University, Changchun 130021, ChinaDepartment of Cancer Center, The First Hospital of Jilin University, Changchun 130021, ChinaImmune cells play an important role in the development and progression of hepatitis C virus (HCV) and hepatocellular carcinoma (HCC). We conducted a retrospective study to evaluate the influence of adoptive cellular immunotherapy (CIT) on viral load and progression-free survival (PFS) for HCC patients infected with HCV. Patients (n=104) were divided into a control group (conventional therapy, n=73) and study group (combination of CIT and conventional therapy, n=31). Autologous mononuclear cells were induced into natural killer, γδT, and cytokine-induced killer cells and infused intravenously to study group patients. More patients had shown viral load decrease or were stable in study group (100% versus 75%) (p=0.014). The median PFS of the study group and control group was 16 and 10 months, respectively (p=0.0041), and only CIT was an independent prognostic factor for PFS (hazard ratio, 0.422; p=0.005). Three patients developed transient moderate fever after infusion, and there were no significant differences in alanine aminotransferase and aspartate aminotransferase levels before and after treatment in both groups. Our results show that CIT contributes to improvement of prognosis and inhibition of viral replication in HCV-related HCC patients, without impairment of liver function.http://dx.doi.org/10.1155/2016/6837241 |
| spellingShingle | Lei Qian Nanya Wang Huimin Tian Haofan Jin Hengjun Zhao Chao Niu Hua He Tingwen Ge Wei Han Jifan Hu Dan Li Fujun Han Jianting Xu Xiao Ding Jingtao Chen Wei Li Jiuwei Cui Dual Effects of Cellular Immunotherapy in Inhibition of Virus Replication and Prolongation of Survival in HCV-Positive Hepatocellular Carcinoma Patients Journal of Immunology Research |
| title | Dual Effects of Cellular Immunotherapy in Inhibition of Virus Replication and Prolongation of Survival in HCV-Positive Hepatocellular Carcinoma Patients |
| title_full | Dual Effects of Cellular Immunotherapy in Inhibition of Virus Replication and Prolongation of Survival in HCV-Positive Hepatocellular Carcinoma Patients |
| title_fullStr | Dual Effects of Cellular Immunotherapy in Inhibition of Virus Replication and Prolongation of Survival in HCV-Positive Hepatocellular Carcinoma Patients |
| title_full_unstemmed | Dual Effects of Cellular Immunotherapy in Inhibition of Virus Replication and Prolongation of Survival in HCV-Positive Hepatocellular Carcinoma Patients |
| title_short | Dual Effects of Cellular Immunotherapy in Inhibition of Virus Replication and Prolongation of Survival in HCV-Positive Hepatocellular Carcinoma Patients |
| title_sort | dual effects of cellular immunotherapy in inhibition of virus replication and prolongation of survival in hcv positive hepatocellular carcinoma patients |
| url | http://dx.doi.org/10.1155/2016/6837241 |
| work_keys_str_mv | AT leiqian dualeffectsofcellularimmunotherapyininhibitionofvirusreplicationandprolongationofsurvivalinhcvpositivehepatocellularcarcinomapatients AT nanyawang dualeffectsofcellularimmunotherapyininhibitionofvirusreplicationandprolongationofsurvivalinhcvpositivehepatocellularcarcinomapatients AT huimintian dualeffectsofcellularimmunotherapyininhibitionofvirusreplicationandprolongationofsurvivalinhcvpositivehepatocellularcarcinomapatients AT haofanjin dualeffectsofcellularimmunotherapyininhibitionofvirusreplicationandprolongationofsurvivalinhcvpositivehepatocellularcarcinomapatients AT hengjunzhao dualeffectsofcellularimmunotherapyininhibitionofvirusreplicationandprolongationofsurvivalinhcvpositivehepatocellularcarcinomapatients AT chaoniu dualeffectsofcellularimmunotherapyininhibitionofvirusreplicationandprolongationofsurvivalinhcvpositivehepatocellularcarcinomapatients AT huahe dualeffectsofcellularimmunotherapyininhibitionofvirusreplicationandprolongationofsurvivalinhcvpositivehepatocellularcarcinomapatients AT tingwenge dualeffectsofcellularimmunotherapyininhibitionofvirusreplicationandprolongationofsurvivalinhcvpositivehepatocellularcarcinomapatients AT weihan dualeffectsofcellularimmunotherapyininhibitionofvirusreplicationandprolongationofsurvivalinhcvpositivehepatocellularcarcinomapatients AT jifanhu dualeffectsofcellularimmunotherapyininhibitionofvirusreplicationandprolongationofsurvivalinhcvpositivehepatocellularcarcinomapatients AT danli dualeffectsofcellularimmunotherapyininhibitionofvirusreplicationandprolongationofsurvivalinhcvpositivehepatocellularcarcinomapatients AT fujunhan dualeffectsofcellularimmunotherapyininhibitionofvirusreplicationandprolongationofsurvivalinhcvpositivehepatocellularcarcinomapatients AT jiantingxu dualeffectsofcellularimmunotherapyininhibitionofvirusreplicationandprolongationofsurvivalinhcvpositivehepatocellularcarcinomapatients AT xiaoding dualeffectsofcellularimmunotherapyininhibitionofvirusreplicationandprolongationofsurvivalinhcvpositivehepatocellularcarcinomapatients AT jingtaochen dualeffectsofcellularimmunotherapyininhibitionofvirusreplicationandprolongationofsurvivalinhcvpositivehepatocellularcarcinomapatients AT weili dualeffectsofcellularimmunotherapyininhibitionofvirusreplicationandprolongationofsurvivalinhcvpositivehepatocellularcarcinomapatients AT jiuweicui dualeffectsofcellularimmunotherapyininhibitionofvirusreplicationandprolongationofsurvivalinhcvpositivehepatocellularcarcinomapatients |